Laboratory Medicine ›› 2019, Vol. 34 ›› Issue (12): 1139-1144.DOI: 10.3969/j.issn.1673-8640.2019.12.017
Previous Articles Next Articles
ZHANG Ping1, YANG Bo2, CAI Xiaoling3, XIONG Wanyuan1, WEI Xupan1, TIE Baoxia1
Received:
2018-12-11
Online:
2019-12-30
Published:
2020-01-03
CLC Number:
ZHANG Ping, YANG Bo, CAI Xiaoling, XIONG Wanyuan, WEI Xupan, TIE Baoxia. Research progress and diagnostic value of exosome microRNA[J]. Laboratory Medicine, 2019, 34(12): 1139-1144.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2019.12.017
miRNA 种类 | 标本 类型 | 分析方法 | 肿瘤 种类 | 敏感性 | 特异性 | 实验组 样本例数 | 对照组 样本例数 |
---|---|---|---|---|---|---|---|
miRNA-21[ | 血清 | qRT-PCR(TaqMan) | 胰腺癌 | 0.81 | 0.82 | 32 | 22 |
miRNA-191[ | 0.72 | 0.86 | |||||
miRNA-451a[ | 0.66 | 0.86 | |||||
miRNA-106a-5p,miRNA-19b-3p[ | 血清 | qRT-PCR(TaqMan) | 胃癌 | 0.95 | 0.90 | 20 | 20 |
miRNA-19b3p,miRNA-21-5p,miRNA-221-3p, miRNA-409-3p,miRNA-425-5p,miRNA-584-5p[ | 血浆 | qRT-PCR(SYBR) | 肺癌 | 0.70 | 0.73 | 141 | 124 |
miRNA-let-7a[ | 血浆 | qRT-PCR(TaqMan) | 胰腺癌 | 1.00 | 1.00 | 29 | 11 |
miRNA-10b[ | 1.00 | 1.00 | |||||
miRNA-21[ | 1.00 | 1.00 | |||||
miRNA-30c[ | 1.00 | 1.00 | |||||
miRNA-181a[ | 1.00 | 1.00 | |||||
miRNA-let-7b-5p,miRNA-let-7e-5p,miRNA-23a-3p, miRNA-486-5p[ | 血浆 | qRT-PCR(TaqMan) | 肺癌 | 0.91 | 0.92 | 47 | 13 |
miRNA-196a[ | 尿液 | 高通量测序 | 前列腺癌 | 0.90 | 1.00 | 20 | 9 |
miRNA-19b[ | 尿液 | qRT-PCR(TaqMan) | 前列腺癌 | 0.94 | 0.80 | 35 | 35 |
miRNA-25[ | 0.71 | 0.69 | |||||
miRNA-125b[ | 0.86 | 0.66 | |||||
miRNA-205[ | 0.57 | 0.74 | |||||
miRNA-200a[ | 血清 | qRT-PCR(TaqMan) | 卵巢癌 | 0.84 | 0.90 | 163 | 20 |
miRNA-200b[ | 0.53 | 1.00 | |||||
miRNA-200c[ | 0.31 | 1.00 | |||||
miRNA-200a,miRNA-200b,miR200c[ | 0.88 | 0.90 | |||||
miRNA-21-5p[ | 尿液 | qRT-PCR(SYBR) | 前列腺癌 | 0.66 | 0.94 | 35 | 35 |
miRNA-141-5p[ | 0.66 | 0.94 | |||||
miRNA-574-3p[ | 0.86 | 1.00 | |||||
miRNA-210[ | 血清 | qRT-PCR(SYBR) | 肾细胞癌 | 0.70 | 0.63 | 82 | 80 |
miRNA-1233[ | 0.82 | 0.76 | |||||
miRNA-16-5p[ | 血清 | miRNA芯片 | 食管癌 | 0.78 | 0.79 | 18 | 29 |
miRNA-16-5p,miRNA-25-3p/miRNA-320a, let-7e-5p/miR15b-5p, miRNA-30a-5p/miRNA-324-5p, miRNA-17-5p/miRNA-194-5p[ | 0.94 | 1.00 | |||||
miRNA-126-3p,miRNA-449a[ | 尿液 | qRT-PCR(TaqMan) | 肾细胞癌 | 0.79 | 0.71 | 109 | 51 |
miRNA-126-3p,miRNA-34b-5p[ | 0.84 | 0.67 | |||||
miRNA-21[ | 血清 | qRT-PCR(SYBR) | 喉癌 | 0.69 | 0.77 | 52 | 49 |
miRNA-23a[ | 血清 | miRNA芯片 | 结肠癌 | 0.92 | 1.00 | 88 | 11 |
miRNA-1246[ | 0.95 | 0.91 | |||||
miRNA-1246,miRNA-4644,miRNA-3976,miRNA-4306[ | 血清 | qRT-PCR(SYBR) | 胰腺癌 | 0.80 | 1.00 | 12 | 75 |
miRNA-151a-5p,miRNA-30a-3p,miRNA-200b-5p, miRNA-629,miRNA-100,miRNA-154-3p[ | 血浆 | qRT-PCR(SYBR) | 肺癌 | 0.96 | 0.60 | 50 | 30 |
miRNA 种类 | 标本 类型 | 分析方法 | 肿瘤 种类 | 敏感性 | 特异性 | 实验组 样本例数 | 对照组 样本例数 |
---|---|---|---|---|---|---|---|
miRNA-21[ | 血清 | qRT-PCR(TaqMan) | 胰腺癌 | 0.81 | 0.82 | 32 | 22 |
miRNA-191[ | 0.72 | 0.86 | |||||
miRNA-451a[ | 0.66 | 0.86 | |||||
miRNA-106a-5p,miRNA-19b-3p[ | 血清 | qRT-PCR(TaqMan) | 胃癌 | 0.95 | 0.90 | 20 | 20 |
miRNA-19b3p,miRNA-21-5p,miRNA-221-3p, miRNA-409-3p,miRNA-425-5p,miRNA-584-5p[ | 血浆 | qRT-PCR(SYBR) | 肺癌 | 0.70 | 0.73 | 141 | 124 |
miRNA-let-7a[ | 血浆 | qRT-PCR(TaqMan) | 胰腺癌 | 1.00 | 1.00 | 29 | 11 |
miRNA-10b[ | 1.00 | 1.00 | |||||
miRNA-21[ | 1.00 | 1.00 | |||||
miRNA-30c[ | 1.00 | 1.00 | |||||
miRNA-181a[ | 1.00 | 1.00 | |||||
miRNA-let-7b-5p,miRNA-let-7e-5p,miRNA-23a-3p, miRNA-486-5p[ | 血浆 | qRT-PCR(TaqMan) | 肺癌 | 0.91 | 0.92 | 47 | 13 |
miRNA-196a[ | 尿液 | 高通量测序 | 前列腺癌 | 0.90 | 1.00 | 20 | 9 |
miRNA-19b[ | 尿液 | qRT-PCR(TaqMan) | 前列腺癌 | 0.94 | 0.80 | 35 | 35 |
miRNA-25[ | 0.71 | 0.69 | |||||
miRNA-125b[ | 0.86 | 0.66 | |||||
miRNA-205[ | 0.57 | 0.74 | |||||
miRNA-200a[ | 血清 | qRT-PCR(TaqMan) | 卵巢癌 | 0.84 | 0.90 | 163 | 20 |
miRNA-200b[ | 0.53 | 1.00 | |||||
miRNA-200c[ | 0.31 | 1.00 | |||||
miRNA-200a,miRNA-200b,miR200c[ | 0.88 | 0.90 | |||||
miRNA-21-5p[ | 尿液 | qRT-PCR(SYBR) | 前列腺癌 | 0.66 | 0.94 | 35 | 35 |
miRNA-141-5p[ | 0.66 | 0.94 | |||||
miRNA-574-3p[ | 0.86 | 1.00 | |||||
miRNA-210[ | 血清 | qRT-PCR(SYBR) | 肾细胞癌 | 0.70 | 0.63 | 82 | 80 |
miRNA-1233[ | 0.82 | 0.76 | |||||
miRNA-16-5p[ | 血清 | miRNA芯片 | 食管癌 | 0.78 | 0.79 | 18 | 29 |
miRNA-16-5p,miRNA-25-3p/miRNA-320a, let-7e-5p/miR15b-5p, miRNA-30a-5p/miRNA-324-5p, miRNA-17-5p/miRNA-194-5p[ | 0.94 | 1.00 | |||||
miRNA-126-3p,miRNA-449a[ | 尿液 | qRT-PCR(TaqMan) | 肾细胞癌 | 0.79 | 0.71 | 109 | 51 |
miRNA-126-3p,miRNA-34b-5p[ | 0.84 | 0.67 | |||||
miRNA-21[ | 血清 | qRT-PCR(SYBR) | 喉癌 | 0.69 | 0.77 | 52 | 49 |
miRNA-23a[ | 血清 | miRNA芯片 | 结肠癌 | 0.92 | 1.00 | 88 | 11 |
miRNA-1246[ | 0.95 | 0.91 | |||||
miRNA-1246,miRNA-4644,miRNA-3976,miRNA-4306[ | 血清 | qRT-PCR(SYBR) | 胰腺癌 | 0.80 | 1.00 | 12 | 75 |
miRNA-151a-5p,miRNA-30a-3p,miRNA-200b-5p, miRNA-629,miRNA-100,miRNA-154-3p[ | 血浆 | qRT-PCR(SYBR) | 肺癌 | 0.96 | 0.60 | 50 | 30 |
[1] | BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424. |
[2] | CHEN W,ZHENG R,ZHANG S,et al.Cancer incidence and mortality in China,2013[J]. Cancer Lett,2017,401:63-71. |
[3] | YANG H,FU H,XU W,et al.Exosomal non-coding RNAs:a promising cancer biomarker[J]. Clin Chem Lab Med,2016,54(12):1871-1879. |
[4] | WU L,QU X.Cancer biomarker detection:recent achievements and challenges[J]. Chem Soc Rev,2015,44(10):2963-2997. |
[5] | THIND A,WILSON C.Exosomal miRNAs as cancer biomarkers and therapeutic targets[J]. J Extracell Vesicles,2016,5:31292. |
[6] | PAN B T,JOHNSTONE R M.Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro:selective externalization of the receptor[J]. Cell,1983,33(3):967-978. |
[7] | SALEHI M,SHARIFI M.Exosomal miRNAs as novel cancer biomarkers:challenges and opportunities[J]. J Cell Physiol,2018,233(9):6370-6380. |
[8] | VALADI H,EKSTRÖM K,BOSSIOS A,et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells[J]. Nat Cell Biol,2007,9(6):654-659. |
[9] | WEBER J A,BAXTER D H,ZHANG S,et al.The microRNA spectrum in 12 body fluids[J]. Clin Chem,2010,56(11):1733-1741. |
[10] | REKKER K,SAARE M,ROOST A M,et al.Comparison of serum exosome isolation methods for microRNA profiling[J]. Clin Biochem,2014,47(1-2):135-138. |
[11] | DING M,WANG C,LU X,et al.Comparison of commercial exosome isolation kits for circulating exosomal microRNA profiling[J]. Anal Bioanal Chem,2018,410(16):3805-3814. |
[12] | OSTENFELD M S,JEPPESEN D K,LAURBERG J R,et al.Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties[J]. Cancer Res,2014,74(20):5758-5771. |
[13] | YE S B,LI Z L,LUO D H,et al.Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma[J]. Oncotarget,2014,5(14):5439-5452. |
[14] | LI J,YU J,ZHANG H,et al.Exosomes-derived MiR-302b suppresses lung cancer cell proliferation and migration via TGFβRⅡ inhibition[J]. Cell Physiol Biochem,2016,38(5):1715-1726. |
[15] | LIAO J,LIU R,SHI Y J,et al.Exosome-shuttling microRNA-21 promotes cell migration and invasion-targeting PDCD4 in esophageal cancer[J]. Int J Oncol,2016,48(6):2567-2579. |
[16] | SINGH R,POCHAMPALLY R,WATABE K,et al.Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer[J]. Mol Cancer,2014,13:256. |
[17] | THIND A,WILSON C.Exosomal miRNAs as cancer biomarkers and therapeutic targets[J]. J Extracell Vesicles,2016,5:31292. |
[18] | LIU Y,LUO F,WANG B,et al.STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells[J]. Cancer Lett,2016,370(1):125-135. |
[19] | MAO G,LIU Y,FANG X,et al.Tumor-derived microRNA-494 promotes angiogenesis in non-small cell lung cancer[J]. Angiogenesis,2015,18(3):373-382. |
[20] | ZHANG L,ZHANG S,YAO J,et al.Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth[J]. Nature,2015,527(7576):100-104. |
[21] | GOTO T,FUJIYA M,KONISHI H,et al.An elevated expression of serum exosomal microRNA-191,-21,-451a of pancreatic neoplasm is considered to be efficient diagnostic marker[J]. BMC Cancer,2018,18(1):116. |
[22] | WANG N,WANG L,YANG Y,et al.A serum exosomal microRNA panel as a potential biomarker test for gastric cancer[J]. Biochem Biophys Res Commun,2017,493(3):1322-1328. |
[23] | ZHOU X,WEN W,SHAN X,et al.A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis[J]. Oncotarget,2017,8(4):6513-6525. |
[24] | LAI X,WANG M,MCELYEA S D,et al.A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer[J]. Cancer Lett,2017,393:86-93. |
[25] | JIN X,CHEN Y,CHEN H,et al.Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing[J]. Clin Cancer Res,2017,23(17):5311-5319. |
[26] | RODRÍGUEZ M,BAJO-SANTOS C,HESSVIK N P,et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes[J]. Mol Cancer,2017,16(1):156. |
[27] | BRYZGUNOVA OE,ZARIPOV M M,SKVORTSOVA T E,et al.Comparative study of extracellular vesicles from the urine of healthy individuals and prostate cancer patients[J]. PLoS One,2016,11(6):e0157566. |
[28] | MENG X,MÜLLER V,MILDE-LANGOSCH K,et al. Diagnostic and prognostic relevance of circulating exosomal miR-373,miR-200a,miR-200b and miR-200c in patients with epithelial ovarian cancer[J]. Oncotarget,2016,7(13):16923-16935. |
[29] | SAMSONOV R,SHTAM T,BURDAKOV V,et al.Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis:application for prostate cancer diagnostic[J]. Prostate,2016,76(1):68-79. |
[30] | ZHANG W,NI M,SU Y,et al.MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma[J]. Eur Urol Focus,2016,4(3):412-419. |
[31] | CHIAM K,WANG T,WATSON D I,et al.Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma[J]. J Gastrointest Surg,2015,19(7):1208-1215. |
[32] | BUTZ H,NOFECH-MOZES R,DING Q,et al.Exosomal microRNAs are diagnostic biomarkers and can mediate cell-cell communication in renal cell carcinoma[J]. Eur Urol Focus,2016,2(2):210-218. |
[33] | WANG J,ZHOU Y,LU J,et al.Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma[J]. Med Oncol,2014,31(9):148. |
[34] | OGATA-KAWATA H,IZUMIYA M,KURIOKA D,et al.Circulating exosomal microRNAs as biomarkers of colon cancer[J]. PLoS One,2014,9(4):e92921. |
[35] | MADHAVAN B,YUE S,GALLI U,et al.Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity[J]. Int J Cancer,2015,136(11):2616-2627. |
[36] | CAZZOLI R,BUTTITTA F,DI NICOLA M,et al.MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer[J]. J Thorac Oncol,2013,8(9):1156-1162. |
[37] | HIZIR M S,BALCIOGLU M,RANA M,et al.Simultaneous detection of circulating oncomiRs from body fluids for prostate cancer staging using nanographene oxide[J]. ACS Appl Mater Interfaces,2014,6(17):14772-14778. |
[38] | LODES M J,CARABALLO M,SUCIU D,et al.Detection of cancer with serum miRNAs on an oligonucleotide microarray[J]. PLoS One,2009,4(7):e6229. |
[39] | EICHELSER C,STÜCKRATH I,MÜLLER V,et al. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients[J]. Oncotarget,2014,5(20): 9650-9663. |
[40] | LIU T,CHEN G,SUN D,et al.Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma[J]. Acta Biochimica Biophys Sin(Shanghai),2017,49(9):808-816. |
[41] | QUE R,DING G,CHEN J,et al.Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma[J]. World J Surg Oncol,2013,11:219. |
[42] | WANG Y,ZHANG C,ZHANG P,et al.Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma[J]. Cancer Med,2018,7(5):1670-1679. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||